Shoulder Innovations vs Treace Medical Concepts
SI and TMCI side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SI and TMCI compare
Shoulder Innovations is the larger company, worth 1.3 times as much as Treace Medical Concepts ($431M against $343M).
Shoulder Innovations grew revenue faster over the last twelve months (54.9% versus −7.1% for Treace Medical Concepts).
Treace Medical Concepts keeps more of each dollar of sales as profit, with a net margin of −27.4% compared with −51.7% at Shoulder Innovations.
Shoulder Innovations scores higher on the StockData Score (8 against 4 for Treace Medical Concepts), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SI | TMCI |
|---|---|---|
| Size and price | ||
| Market cap | $431M | $343M |
| Share price | $20.69 | $5.27 |
| Change, 1 year | 37.9% | 58.5% |
| Change, 5 years | – | −73.1% |
| Beta (5Y) | – | 1.70 |
| Employees | 75 | 450 |
| StockData Score | ||
| Total score | 8 (better) | 4 |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 (better) | 1 |
| Performance score | 1 (better) | 0 |
| Health score | 4 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 6.7× | 1.7× (better) |
| P/B | 3.6× (better) | 5.6× |
| FCF yield | −9.9% | −5.4% (better) |
| Fair value | $13.60 | $6.26 |
| Margin of safety | −52.1% | 15.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 54.9% (better) | −7.1% |
| Revenue growth, 5Y average | – | 30.0% |
| Profitability | ||
| Gross margin | 77.8% | 79.6% (better) |
| Operating margin | −54.4% | −24.4% (better) |
| Net margin | −51.7% | −27.4% (better) |
| FCF margin | −66.2% | −9.1% (better) |
| Return on equity | −25.1% (better) | −74.0% |
| Return on invested capital | −83.6% | −46.4% (better) |
| Financial health | ||
| Debt / equity | 0.13 (better) | 0.97 |
| Interest coverage | – | −8.2× |
| Current ratio | 10.68 (better) | 2.58 |
| Altman Z-score | 8.96 (better) | 0.15 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 39.8% | 49.0% |
| Held by insiders | 40.0% | 28.0% |
| Insider net buying, 12 months | −$5.3M | $1.5M (better) |
| Short interest, % of float | 5.7% | 3.8% |
Go deeper
- SI stock overview
- SI income statement
- SI valuation and score
- TMCI stock overview
- TMCI income statement
- TMCI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.